Institutional shares held 45.2 Million
165K calls
33.6K puts
Total value of holdings $222M
$813K calls
$165K puts
Market Cap $278M
56,561,500 Shares Out.
Institutional ownership 79.95%
# of Institutions 161


Latest Institutional Activity in VNDA

Top Purchases

Q3 2024
Goldman Sachs Group Inc Shares Held: 760K ($3.74M)
Q3 2024
Millennium Management LLC Shares Held: 400K ($1.97M)
Q3 2024
Dimensional Fund Advisors LP Shares Held: 2.26M ($11.1M)
Q3 2024
Tang Capital Management LLC Shares Held: 2.35M ($11.6M)
Q3 2024
Vanguard Group Inc Shares Held: 3.63M ($17.9M)

Top Sells

Q3 2024
Nuveen Asset Management, LLC Shares Held: 155K ($761K)
Q3 2024
Krensavage Asset Management, LLC Shares Held: 415K ($2.04M)
Q3 2024
Profit Investment Management, LLC Shares Held: 330K ($1.62M)
Q3 2024
Bml Capital Management, LLC Shares Held: 229K ($1.12M)
Q3 2024
D. E. Shaw & Co., Inc. Shares Held: 560K ($2.75M)

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.


Insider Transactions at VNDA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
962K Shares
From 10 Insiders
Grant, award, or other acquisition 962K shares
Sell / Disposition
128K Shares
From 6 Insiders
Open market or private sale 128K shares

Track Institutional and Insider Activities on VNDA

Follow Vanda Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VNDA shares.

Notify only if

Insider Trading

Get notified when an Vanda Pharmaceuticals Inc. insider buys or sells VNDA shares.

Notify only if

News

Receive news related to Vanda Pharmaceuticals Inc.

Track Activities on VNDA